This observational study is looking at how becoming a first-time parent affects the health of people with cystic fibrosis (CF) in the United States, especially with the use of highly effective CFTR modulator medicines like elexacaftor/tezacaftor/ivacaftor. We want to understand if parents with CF who experience moderate to severe depression have a faster decline in their lung function (measured by Forced Expiratory Volume, FEV1) compared to those with less or no depression. To join, you must be at least 18 years old, have a CF diagnosis, and have become a first-time parent (including foster, step, adoptive, or legal guardian) to a child under 5 years old within the last 180 days. You cannot have had a lung transplant or be unable to speak/read English or Spanish. The study is currently unclear on its recruitment status.

Study design

This is an observational study involving 146 new parents with CF. It is not a drug trial, but rather looks at the impact of parenthood.

What's involved

You will be followed annually for up to 5 years after becoming a parent. The study will collect physical and mental health data, including your lung function (FEV1) and surveys.

Compensation

Not stated in the trial record.

Follow-up

Your lung function (FEV1) will be measured annually from 2 years prior to enrollment and annually for Year 1 through Year 5 after becoming a parent.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.